Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Elliott Barnathan"'
Autor:
Maarten L. Simoons, Stefan James, Elliott Barnathan, Agneta Siegbahn, Paul W. Armstrong, Lars Wallentin, Robert M. Califf
Publikováno v:
American Heart Journal. 147:267-274
Background In acute coronary syndromes, the inflammation and the coagulation systems are activated, implying an impaired outcome. In addition to platelet inhibition, recent evidence suggests that the glycoprotein IIb/IIIa receptor inhibitor abciximab
Autor:
Paul W. Armstrong, Judith Cooper, Stefan James, Erik Magnus Ohman, Eric Boersma, M. L. Simoons, Lars Wallentin, J.P. Ottervanger, Elliott Barnathan
Publikováno v:
European Heart Journal, 25, 1494-1501. Oxford University Press
Background Immediate, as well as early, revascularisation is of benefit in patients with acute coronary syndromes (ACS) presenting with ST elevation. However, trials comparing invasive versus medical treatment in patients with an acute coronary syndr
Autor:
Bertil Lindahl, Maarten L. Simoons, Paul W. Armstrong, Eric J. Topol, Per Venge, Gusto-Iv–Acs Investigators, Stefan James, Agneta Siegbahn, Robert M. Califf, Elliott Barnathan, Lars Wallentin
Publikováno v:
Journal of the American College of Cardiology. 41(6):916-924
OBJECTIVES We sought to evaluate C-reactive protein (CRP) and troponin T (TnT) as predictors of risk of the individual end points of mortality and myocardial infarction (MI) in a large cohort of patients with acute coronary syndrome (ACS). BACKGROUND
Autor:
Maarten L. Simoons, Eric J. Topol, Elliott Barnathan, Lars Wallentin, Stefan James, Paul W. Armstrong, J.S. Cooper, Erik Magnus Ohman, Eric Boersma, J.P. Ottervanger
Publikováno v:
Circulation, 107, 437-442. Lippincott Williams & Wilkins
Background— This study was designed to investigate long-term effects of the glycoprotein IIb/IIIa inhibitor abciximab in patients with acute coronary syndrome without ST elevation who were not scheduled for coronary intervention. Methods and Result
Autor:
Stefan K, James, Agneta, Siegbahn, Paul, Armstrong, Elliott, Barnathan, Robert, Califf, Maarten L, Simoons, Lars, Wallentin
Publikováno v:
American heart journal. 147(2)
In acute coronary syndromes, the inflammation and the coagulation systems are activated, implying an impaired outcome. In addition to platelet inhibition, recent evidence suggests that the glycoprotein IIb/IIIa receptor inhibitor abciximab attenuates
Autor:
Stefan K, James, Paul, Armstrong, Elliott, Barnathan, Robert, Califf, Bertil, Lindahl, Agneta, Siegbahn, Maarten L, Simoons, Eric J, Topol, Per, Venge, Lars, Wallentin
Publikováno v:
Journal of the American College of Cardiology. 41(6)
We sought to evaluate C-reactive protein (CRP) and troponin T (TnT) as predictors of risk of the individual end points of mortality and myocardial infarction (MI) in a large cohort of patients with acute coronary syndrome (ACS).Both CRP and TnT predi
Publikováno v:
ACC Current Journal Review. 13:35
Autor:
George W. Vetrovec, James R. Margolis, Hal Whitworth, Carl J. Pepine, Sheldon Goldberg, Elliott Barnathan, Andrew S. Taussig, Germano DiSciascio, Robert C. MacDonald, Ralph Hugo, John W. Hirshfeld, Theodore A. Bass, Mike Savage, Michael J. Cowley
Publikováno v:
Journal of the American College of Cardiology. 15:A59